Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2004, Vol. 9 ›› Issue (11): 1205-1208.
Previous Articles Next Articles
HUANG Xiao-Hui, LI Jun
Received:
2004-09-14
Revised:
2004-10-08
Online:
2004-11-26
Published:
2020-11-19
CLC Number:
HUANG Xiao-Hui, LI Jun. Current researches on pharmacokinetic/pharmacodynamic (PK/PD) modelling[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(11): 1205-1208.
Add to citation manager EndNote|Ris|BibTeX
URL: https://manu41.magtech.com.cn/Jweb_clyl/EN/
https://manu41.magtech.com.cn/Jweb_clyl/EN/Y2004/V9/I11/1205
1 Law FCP,何绍雄.药代动力学-药效学结合模型的应用进展[J].国外医学药学分册,2001; 8(1): 1-5 2 戴光强.医院药学(进展篇)[M].合肥:安徽科技出版社,2001: 252-9 3 Meibohm B, Derendorf. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling[J]. Int J Clin Pharma-col Ther,1997;35(10): 401-13 4 凌树森.治疗药物监测新理论与新方法[M].中国医药科技出版社,2002: 106-32 5 NONMEN Project Group. NONMEN users guide, part 1-6 [M]. University of California: SanFrancisco, 1989 6 Holford NHG, Sheiner LB. Understanding the dose-effect rela-tionship: clinical application of pharmacokinetic-pharmacody-namic models [J]. Clin Pharmacokinet, 1981; 6(6): 429 7 Sun YN, EhjBios DC, Almon RR, Pyszczyhski NA, Jusko WJ. Dose-dependence and repeated-dose studies for receptor/gene-mediated phannacodynamic of methylprednisolone on glucocorti-coid receptor down-regulation and tyrosine aminotransferase in-duction in rat liver[J]. J Pliarmacokinet Biopharm, 1998; 26(6):619-48 8 Katashima M, Yamada Y, Yamamoto K, Kotaki H, Sato H, Sawada Y. Anajysis of antiplatelet effect of ticlopidine in hu-mans: mtxleling based on irreversible inhibition of platelet pre-cursors in bone marrow[J]. J Pharmocokinet Biopharm, 1999; 27(3):283-96 |
[1] | LU Kepeng, LIU Caihong, BI Ying. Effect of prophylactic anticoagulation duration on venous thrombosis after total hip/knee arthroplasty [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1269-1274. |
[2] | LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282. |
[3] | JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120. |
[4] | LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130. |
[5] | LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138. |
[6] | JIANG Daoli, CHOU Xiaohua, LIU Zhidong, LI Wei, ZHANG Bo, XU Sang, TAN Defei, FANG Yi, LV Dongmei, WANG Tao. Real-world study of ceftazidime-avibactam in the treatment of multidrug-resistant gram-negative bacterial infections [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1008-1017. |
[7] | WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033. |
[8] | WANG Fei, HANG Yongfu, WANG Wei. Influence of argumented renal clearance on teicoplannin serum concentrations in critical ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1043-1048. |
[9] | HUA Zhihui, LIU Dong, ZHANG Jiandong, CAI Siyu, GE Chunli, CHEN Nan, QI Qi. Clinical evaluation of the efficacy against helicobacter pylori by amoxicillin from volume-based procurement and potassium amoxicillin clavulanate [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1061-1066. |
[10] | ZHONG Wei, SHI Shuxia, QIN Qinyue, YU Guo. Measurement tools and rationality evaluation of clinical research coordinator's work ability and workload [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 937-947. |
[11] | LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HE Qing, HUANG Kai. Analysis of reasons for screening failure of healthy subjects in clinical trials of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 758-766. |
[12] | LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774. |
[13] | LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640. |
[14] | HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535. |
[15] | SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||